Repligen Co. (NASDAQ:RGEN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Repligen Co. (NASDAQ:RGEN) have earned a consensus rating of “Moderate Buy” from the fourteen research firms that are covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $184.73.

RGEN has been the subject of a number of research reports. Wolfe Research assumed coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. HC Wainwright reduced their price objective on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company.

Hedge Funds Weigh In On Repligen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ballentine Partners LLC lifted its stake in shares of Repligen by 4.0% in the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 72 shares in the last quarter. CIBC Asset Management Inc increased its holdings in Repligen by 5.0% during the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 81 shares during the last quarter. MML Investors Services LLC raised its position in shares of Repligen by 2.7% in the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 90 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in shares of Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after buying an additional 100 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Up 1.2 %

RGEN opened at $161.93 on Thursday. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13. The business has a 50-day moving average of $155.02 and a two-hundred day moving average of $148.41. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $9.07 billion, a price-to-earnings ratio of -437.64, a price-to-earnings-growth ratio of 4.67 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.23 earnings per share. On average, research analysts expect that Repligen will post 1.54 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.